Literature DB >> 2907786

Quantitative structure-activity study on human pharmacokinetic parameters of benzodiazepines using the graph theoretical approach.

R S Markin1, W J Murray, H Boxenbaum.   

Abstract

The graph theoretical indices for a series of 13 benzodiazepines were calculated using a graph-path topological method. The total molecule, the ring fragments, and combinations of ring fragments were subjected to a quantitative structure-activity analysis using eight pharmacokinetic parameters. The metabolic clearance and the blood-to-plasma concentration ratios were most highly correlated with the graph theoretical indices, with R values of 0.975 and 0.938, respectively. These correlations were found when the diazepine + benzo fragment and phenyl fragment were used to calculate the graph-path indices. Terminal disposition half-life was correlated with the benzo + diazepine fragment, with R = 0.969. Truncating the graph-path codes by eliminating cycles in the total molecule markedly improved the correlation coefficients. When compared to the graph-path indices for the total molecule, the correlation coefficients for the terminal disposition half-life and metabolic clearance data rose from 0.721 to 0.935 and from 0.770 to 0.968, respectively, using the graph-path indices of the truncated molecule. Intrinsic clearance of unbound drug also was poorly correlated with the total molecule (r less than 0.7) but rose significantly using the graph-path indices of the truncated molecule (r = 0.971 and 0.975 for the well-stirred and parallel-tube models, respectively).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2907786     DOI: 10.1023/a:1015933527583

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Mathematical description of molecular structure: Molecular topology.

Authors:  H E Simmons; R E Merrifield
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

2.  The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.

Authors:  R W Lucek; C B Coutinho
Journal:  Mol Pharmacol       Date:  1976-07       Impact factor: 4.436

3.  "Anxiety peptide" found in brain.

Authors:  J L Marx
Journal:  Science       Date:  1985-02-22       Impact factor: 47.728

4.  Comparative pharmacokinetics of benzodiazepines in dog and man.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

5.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

6.  Molecular connectivity and substructure analysis.

Authors:  L H Hall; L B Kier
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

7.  Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

8.  Endogenous effector of the benzodiazepine binding site: purification and characterization.

Authors:  J H Woolf; J C Nixon
Journal:  Biochemistry       Date:  1981-07-21       Impact factor: 3.162

  8 in total
  3 in total

1.  Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics.

Authors:  Vangelis Karalis; Anna Tsantili-Kakoulidou; Panos Macheras
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Searching for the endogenous benzodiazepine using the graph theoretical approach.

Authors:  R S Markin; W J Murray
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

Review 3.  Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Authors:  S B Charnick; R Kawai; J R Nedelman; M Lemaire; W Niederberger; H Sato
Journal:  J Pharmacokinet Biopharm       Date:  1995-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.